Bella Kaufman

Summary

Country: Israel

Publications

  1. pmc Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
  2. doi request reprint Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
    Bella Kaufman
    Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Clin Oncol 27:5529-37. 2009
  3. doi request reprint Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
    Bella Kaufman
    The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Lancet Oncol 10:581-8. 2009
  4. doi request reprint Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Shiri Bernholtz
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, 52621 Tel Hashomer, Israel
    Breast Cancer Res Treat 132:669-73. 2012
  5. doi request reprint Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations
    Bella Kaufman
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Fam Cancer 8:473-8. 2009
  6. ncbi request reprint Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation
    Shiri Bernholtz
    Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, 52621, Tel Hashomer, Israel
    Breast Cancer Res Treat 129:557-63. 2011
  7. doi request reprint Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
    Shani Paluch-Shimon
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 32:504-8. 2009
  8. doi request reprint Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel
    Yael Laitman
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, 52621, Israel
    Breast Cancer Res Treat 127:489-95. 2011
  9. doi request reprint Epigenetic silencing of the tumor suppressor klotho in human breast cancer
    Tami Rubinek
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Breast Cancer Res Treat 133:649-57. 2012
  10. doi request reprint SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women
    Shimrit Cohen
    Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Fam Cancer 8:135-44. 2009

Collaborators

Detail Information

Publications24

  1. pmc Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
    ..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens...
  2. doi request reprint Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
    Bella Kaufman
    Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Clin Oncol 27:5529-37. 2009
    ..TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic breast cancer (MBC)...
  3. doi request reprint Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
    Bella Kaufman
    The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Lancet Oncol 10:581-8. 2009
    ..We aimed to assess efficacy of lapatinib in an expanded cohort of patients with relapsed or refractory HER2+ disease...
  4. doi request reprint Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Shiri Bernholtz
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, 52621 Tel Hashomer, Israel
    Breast Cancer Res Treat 132:669-73. 2012
    ..8 cases SIR = 0.84, 95% CI (0.51, 1.30)]. The rate of phenocopy breast cancer in non-carriers from Israeli BRCA1 BRCA2 mutation carrier families is 2.26% with no increased breast cancer risk over the average-risk population...
  5. doi request reprint Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations
    Bella Kaufman
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Fam Cancer 8:473-8. 2009
    ..In conclusion, CHEK2*I157T missense mutation is a founder mutation in ethnically diverse populations, but may also be a mutational hotspot...
  6. ncbi request reprint Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation
    Shiri Bernholtz
    Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, 52621, Tel Hashomer, Israel
    Breast Cancer Res Treat 129:557-63. 2011
    ..The authors conclude that OC use and paternal origin of mutation affect breast cancer penetrance in Jewish BRCA1 and BRCA2 mutation carriers...
  7. doi request reprint Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
    Shani Paluch-Shimon
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 32:504-8. 2009
    ....
  8. doi request reprint Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel
    Yael Laitman
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, 52621, Israel
    Breast Cancer Res Treat 127:489-95. 2011
    ..In conclusion, there are no predominant recurring germline mutations in BRCA1 or BRCA2 genes among ethnically diverse Jewish and non Jewish high risk families in Israel...
  9. doi request reprint Epigenetic silencing of the tumor suppressor klotho in human breast cancer
    Tami Rubinek
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Breast Cancer Res Treat 133:649-57. 2012
    ..Klotho expression and methylation may, therefore, serve as early markers for breast tumorigenesis...
  10. doi request reprint SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women
    Shimrit Cohen
    Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Fam Cancer 8:135-44. 2009
    ..This mutation was not found among 153 high risk, 98 sporadic breast/ovarian cancer patients, or 97 healthy controls. The SULT1E1 gene may need to be further explored as candidate breast cancer gene...
  11. doi request reprint The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Bella Kaufman
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, 52621, Israel
    Breast Cancer Res Treat 126:521-7. 2011
    ..In conclusion, there was no overall evidence for an association of the -34 T > C CYP17 polymorphism with either breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers...
  12. doi request reprint Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women
    Shani Paluch-Shimon
    The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 34:219-22. 2011
    ..Studies have suggested an association between breast cancer at a young age, poorer outcome, and adverse clinical and pathologic characteristics. It is unclear whether age is an independent prognostic factor...
  13. doi request reprint Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel
    Yael Laitman
    Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, 52621 Tel Hashomer, Israel
    Breast Cancer Res Treat 133:1153-7. 2012
    ..Jewish high risk families of North African, Asian, and Balkan descent should be screened for the 981delAT, Tyr978X, A1708E BRCA1, and the R2336P BRCA2 mutations, respectively...
  14. doi request reprint The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer
    Yael Laitman
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, The Chaim Sheba Medical Center, 52621, Tel Hashomer, Israel
    Fam Cancer 11:243-7. 2012
    ..We conclude that the recurring Ashkenazi MSH2 and MSH6 mutations contribute little if any to sporadic and familial gastric and pancreatic cases in Israeli patients...
  15. doi request reprint Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals
    Bella Kaufman
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Genet Test Mol Biomarkers 13:465-9. 2009
    ..The two flanking markers farthest away showed more diversity, between and even within Polish individuals. In conclusion, the *BRCA1 missense mutation is a founder mutation that can be detected in geographically related populations...
  16. doi request reprint The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women
    Tal Distelman Menachem
    The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, 52621 Tel Hashomer, Israel
    Fam Cancer 8:399-402. 2009
    ..Mutations in the coding regions of the RNF146 and ECHDC1 genes do not contribute to the burden of inherited predisposition of breast cancer in Ashkenazi high risk women...
  17. doi request reprint Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women
    Tal Distelman-Menachem
    Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Fam Cancer 8:127-33. 2009
    ..The contribution of major gene rearrangements and seemingly pathogenic missense mutations to inherited breast cancer predisposition has never been systematically evaluated in Ashkenazim...
  18. doi request reprint High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer
    Shani Paluch-Shimon
    The Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Oncol 47:1564-9. 2008
    ....
  19. doi request reprint The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells
    Hagai Ligumsky
    Institute of Oncology, Chaim Sheba Medical Center, 52621 Ramat Gan, Israel
    Breast Cancer Res Treat 132:449-61. 2012
    ..Reduced GLP-1 levels may, therefore, serve as a novel link between obesity, diabetes mellitus, and breast cancer...
  20. ncbi request reprint Pregnancy-associated breast cancer
    Lital Keinan-Boker
    Israel Center for Disease Control, Ministry of Health, Sheba Medical Center of Health Policy Research, Tel Hashomer, Israel
    Isr Med Assoc J 10:722-7. 2008
    ..Women treated with fertility treatment drugs may be at a higher risk for PABC as well...
  21. ncbi request reprint Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study
    Ido Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Cancer 112:731-6. 2008
    ..To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population...
  22. ncbi request reprint Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer
    Yael Laitman
    Oncogenetics Unit, Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 9:791-6. 2007
    ..Indeed, the CHEK2*1100delC truncating mutation was reported in a subset of mostly North European breast cancer families. The rate of the CHEK2*1100delC variant in the Ashkenazi Jewish population was reported to be 0.3%...
  23. doi request reprint Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer
    Moshe Zvi Papa
    Department of Surgery and Surgical Oncology and the Breast Service, Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Surg Oncol 98:403-6. 2008
    ..To address optimal timing of sentinel lymph node biopsy (SLNB) in breast cancer patients undergoing neoadjuvant treatment...
  24. doi request reprint KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer
    Lilach Abramovitz
    Institute of Oncology, The Chaim Sheba Medical Center, Ramat Gan, Tel Aviv, Israel
    Clin Cancer Res 17:4254-66. 2011
    ..Klotho is expressed in the normal pancreas and both the IGF-I and FGF pathways are involved in pancreatic cancer development. We, therefore, undertook to study the expression and activity of klotho in pancreatic cancer...